Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.63 |
| ▸ | TSHR | P16473 | 5/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | HTT | P42858 | 6/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7084470 | 0.86 | HTT (0.52) | ALDH1A1TSHRMAPK1LMNAHTT | |
| SCHEMBL10237222 | 0.83 | HTT (0.82) | ALDH1A1TSHRMAPK1LMNAHTT | |
| SCHEMBL13641084 | 0.82 | HTT (0.80) | ALDH1A1TSHRMAPK1LMNAHTT | |
| SCHEMBL13164948 | 0.79 | HTT (0.75) | ALDH1A1TSHRMAPK1LMNAHTT | |
| SCHEMBL7661912 | 0.76 | DRD2 (1.00) | ALDH1A1TSHRMAPK1LMNAHTT | |
| SCHEMBL12789802 | 0.75 | MEN1 (1.00) | ALDH1A1TSHRMAPK1LMNAHTT | |
| SCHEMBL16406276 | 0.74 | ALDH1A1 (0.68) | ALDH1A1TSHRMAPK1LMNAHTT | |
| SCHEMBL18313846 | 0.73 | HTT (0.65) | ALDH1A1TSHRMAPK1LMNAHTT | |
| SCHEMBL13640907 | 0.72 | HTT (0.63) | ALDH1A1TSHRMAPK1LMNAHTT | |
| SCHEMBL13641058 | 0.72 | HTT (0.67) | ALDH1A1TSHRMAPK1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401840-A4 | NOVEL 4-AMINO-5,6-SUBSTITUTED THIOPHENO 2,3-D|PYRIMIDINES | BAYER CORP (US) | 2007-05-16 | — | — | EP | claimed |
| EP-1401840-A1 | NOVEL 4-AMINO-5,6-SUBSTITUTED THIOPHENO 2,3-D]PYRIMIDINES | Bayer Corporation (US) | 2004-03-31 | — | — | EP | claimed |
| US-20030119829-A1 | 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of PDE7B-mediated diseases and conditions | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2003-06-26 | — | — | US | claimed |
| WO-2002088138-A1 | NOVEL 4-AMINO-5,6-SUBSTITUTED THIOPHENO[2,3-D]PYRIMIDINES | BAYER CORPORATION (US) | 2002-11-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119829-A1 | 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of PDE7B-mediated diseases and conditions | PDE7B, PDE4B, PDE7A | ALDH1A1 1393/4885TSHR 3569/4885MAPK1 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.